Goldman Sachs analyst Richard Law CFA initiates coverage on $Protagonist Therapeutics (PTGX.US)$ with a hold rating, and sets the target price at $47.
According to TipRanks data, the analyst has a success rate of 33.3% and a total average return of 6.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Protagonist Therapeutics (PTGX.US)$'s main analysts recently are as follows:
Protagonist Therapeutics has potential for commercial success with its Phase 3 assets, although they are considered to provide 'limited' financial and mergers and acquisitions upside since they have already been licensed. The significant increase, over 400%, in the stock price of Protagonist over the past two years has been influenced by development progression and licensing agreements, reflecting the current market expectations from both assets.
Protagonist Therapeutics is utilizing its peptide technology platform to tackle disorders in hematology and immunology. The expectation is that the share price will rise as clinical risks are mitigated within its pipeline over the coming year, bolstered by multiple catalysts for rusfertide and JNJ-2113. Protagonist is positioned to offer oral alternatives in major blockbuster categories, which are presently overwhelmed by injectable solutions.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
高盛集團分析師Richard Law CFA首次給予$Protagonist Therapeutics (PTGX.US)$持有評級，目標價47美元。
根據TipRanks數據顯示，該分析師近一年總勝率為33.3%，總平均回報率為6.1%。
此外，綜合報道，$Protagonist Therapeutics (PTGX.US)$近期主要分析師觀點如下：
Protagonist Therapeutics憑藉其第三階段資產有可能取得商業成功，儘管由於已經獲得許可，這些資產被認爲提供 「有限」 的財務和併購上升空間。Protaonist 股價在過去兩年中大幅上漲，超過400％，這是受開發進展和許可協議的影響，反映了當前市場對這兩種資產的預期。
Protagonist Therapeutics正在利用其肽技術平台來解決血液學和免疫學方面的疾病。預計在rusfertide和 JNJ-2113 的多種催化劑的推動下，隨着未來一年其研發中的臨床風險得到緩解，股價將上漲。Protagonist 有望在主要的重磅類別中提供口服替代品，這些類別目前可注射的溶液已不堪重負。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
